TLDR:
- Kirkland advised J.P. Morgan Private Capital on the closing of its biotechnology venture capital fund, 270 Life Sciences Private Capital Fund I, which closed above its $500 million target.
- The fund attracted support from various investors and focuses on investing in private biotechnology companies across different stages, modalities, therapeutic areas, and geographies.
Legal Desire Media and Insights reported that Kirkland recently advised J.P. Morgan Private Capital on the final closing of its inaugural biotechnology venture capital fund, 270 Life Sciences Private Capital Fund I. The fund exceeded its $500 million target and received strong support from investors such as institutional allocators, strategic corporate partners, family offices, and high net worth individuals across North America, Europe, the Middle East, and Asia.
The fund’s investment strategy involves funding private biotechnology companies across various stages, modalities, therapeutic areas, and geographies. The portfolio investments include companies focused on cardiometabolic disease, oncology, immunology, and genetic medicines. Additionally, the fund aims to leverage J.P. Morgan’s resources and scale to add value to its portfolio companies.
The article also highlighted other recent deals in the legal industry, including Latham & Watkins’ involvement in various transactions. Legal Desire Media and Insights aims to provide credible updates and insights in the legal industry for over a decade.
